{"doi":"10.1002/cncr.35084","title":"Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532","abstract":"INTRODUCTION: The prognostic impact of positive lymph nodes (LN+) and/or singular loss of heterozygosity (LOH) of 1p or 16q were assessed in children with stage III favorable histology Wilms tumor (FHWT) enrolled on AREN0532 or AREN03B2 alone. PATIENTS AND METHODS: A total of 635 stage III FHWT vincristine/dactinomycin/doxorubicin (DD4A)-treated patients met inclusion criteria. Event-free survival (EFS) and overall survival are reported overall and by LN sampling, LN status, LOH 1p, LOH 16q, and a combination of LN status and singular LOH. Patients with unknown or positive combined LOH of 1p and 16q status and AREN03B2-only patients with unknown outcomes or treatment other than DD4A were excluded. RESULTS: EFS did not differ by study, supporting pooling. Lack of LN sampling (hazard ratio [HR], 2.12; p = .0037), LN positivity (HR, 2.78; p = .0002), LOH 1p (HR, 2.18; p = .0067), and LOH 16q (HR, 1.72; p = .042) were associated with worse EFS. Compared with patients with both LN- and LOH-, those with negative nodes but positive LOH 1p or 16q and those with LN+ but LOH- for 1p or 16q had significantly worse EFS (HR, 3.05 and 3.57, respectively). Patients positive for both LN and LOH had the worst EFS (HR, 6.33; overall group factor, p < .0001). CONCLUSION: Findings confirm LN+ status as an adverse prognostic factor amplified by presence of singular LOH 1p or 16q, supporting study of intensified therapy for patients with LN+ in combination with singular LOH in a prospective clinical trial.","journal":"Cancer","year":2023,"id":330649,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8431,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":381789,"name":"Lindsay A. Renfro","orcid":"0000-0002-4306-1896","position":1,"is_corresponding":false},{"id":342739,"name":"James I. Geller","orcid":"0000-0001-5181-116X","position":2,"is_corresponding":false},{"id":72709,"name":"Elizabeth J. Perlman","orcid":"0000-0001-6853-6221","position":3,"is_corresponding":false},{"id":342734,"name":"John A. Kalapurakal","orcid":"0000-0001-7405-6769","position":4,"is_corresponding":false},{"id":288903,"name":"Arnold C. Paulino","orcid":"0000-0002-0269-3045","position":5,"is_corresponding":false},{"id":678735,"name":"David Dix","orcid":"0000-0002-1498-5555","position":6,"is_corresponding":false},{"id":1055534,"name":"Meryle J. Eklund","orcid":null,"position":7,"is_corresponding":false},{"id":381384,"name":"Andrew J. Murphy","orcid":"0000-0001-6747-0355","position":8,"is_corresponding":false},{"id":445710,"name":"Rodrigo Romao","orcid":"0000-0001-5786-1002","position":9,"is_corresponding":false},{"id":342732,"name":"Peter F. Ehrlich","orcid":"0000-0001-6161-1815","position":10,"is_corresponding":false},{"id":1051644,"name":"Carly R. Varela","orcid":null,"position":11,"is_corresponding":false},{"id":488172,"name":"Kelly Vallance","orcid":"0000-0003-4185-921X","position":12,"is_corresponding":false},{"id":342741,"name":"Conrad V. Fernandez","orcid":"0000-0002-0746-8306","position":13,"is_corresponding":false},{"id":342742,"name":"Jeffrey S. Dome","orcid":"0000-0002-9037-369X","position":14,"is_corresponding":false},{"id":72710,"name":"Elizabeth A. Mullen","orcid":"0000-0002-6704-0002","position":15,"is_corresponding":false},{"id":1054888,"name":"Nicholas F. Evageliou","orcid":"0000-0002-5567-0007","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-19T01:09:14.691473Z","pmid":"37902955","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}